



1

2

3 [Title page](#)

4 **Predicting the future risk of lung cancer: development and validation of QCancer2 (10-**
5 **year risk) lung model and evaluating the model performance of nine prediction models**

6

7 **Authors**

8 Weiqi Liao, Data Scientist [1]

9 Carol Coupland, Senior Research Fellow [1] and Professor of Medical Statistics in Primary Care [2]

10 Judith Burchardt, GP and Honorary Clinical Researcher [1]

11 David Baldwin, Consultant Respiratory Physician [3] and Honorary Professor of Medicine [2]

12 Collaborators of the DART initiative

13 Fergus Gleeson, Consultant Radiologist and Professor of Radiology [4]

14 Julia Hippisley-Cox, Professor of Clinical Epidemiology and General Practice [1]

15

16 **Institutions and affiliations**

17 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

18 2. School of Medicine, University of Nottingham, Nottingham, UK

19 3. Nottingham University Hospitals NHS Trust, Nottingham, UK

20 4. Department of Oncology, University of Oxford, Oxford, UK

21

22 **Corresponding author**

23 Professor Julia Hippisley-Cox, julia.hippisley-cox@phc.ox.ac.uk

24 Nuffield Department of Primary Care Health Sciences, University of Oxford

25 Radcliffe Observatory Quarter, Woodstock Road, OX2 6GG, Oxford

26

27 **Running head:** Predicting the future risk of lung cancer

28

29 **Word count:** 5679 (main text); 394 (abstract)

1 Abstract

2

3 **Objectives:** To develop and validate the QCancer2 (10-year risk) lung model for estimation of future
4 risk of lung cancer and to compare the model performance against other prediction models for lung
5 cancer screening

6

7 **Design:** open cohort study using linked electronic health records (EHRs) from the QResearch
8 database (1 January 2005 – 31 March 2020)

9

10 **Setting:** English primary care

11

12 **Participants:** 12.99 million patients aged 25-84 years were in the derivation cohort to develop the
13 models and 4.14 million patients were in the validation cohort. All patients were free of lung cancer
14 at baseline.

15

16 **Main outcome measure:** Incident lung cancer cases

17

18 **Methods:** There were two stages in this study. First, Cox proportional hazards models were used in
19 the derivation cohort to update the QCancer (10-year risk) lung model in men and women for a 10-
20 year predictive horizon, including two new predictors (pneumonia and venous thromboembolism)
21 and more recent data. Discrimination measures (Harrell's C, D statistic, and R_D^2) and calibration plots
22 were used to evaluate model performance in the validation cohort by sex. Secondly, seven
23 prediction models for lung cancer screening (LLP_{v2}, LLP_{v3}, LCRAT, PLCO_{M2012}, PLCO_{M2014}, Pittsburgh,
24 and Bach) were selected to compare the model performance with the QCancer2 (10-year risk) lung
25 model in two subgroups: (1) smokers and non-smokers aged 40-84 years and (2) ever-smokers aged
26 55-74 years.

27

28 **Results:** 73,380 incident lung cancer cases were identified in the derivation cohort and 22,838 in the
29 validation cohort during follow-up. The updated models explained 65% of the variation in time to
30 diagnosis of lung cancer (R_D^2) in both sexes. Harrell's C statistics were close to 0.9 (indicating
31 excellent discrimination), and the D statistics were around 2.8. Compared with the original models,
32 the discrimination measures in the updated models improved slightly in both sexes. Compared with
33 other prediction models, the QCancer2 (10-year risk) lung model had the best model performance in

1 discrimination, calibration, and net benefit across three predictive horizons (5, 6, and 10 years) in
2 the two subgroups.

3

4 **Conclusion:** Developed and validated using large-scale EHRs, the QCancer2 (10-year risk) lung model
5 can estimate the risk of an individual patient aged 25-84 years for up to 10 years. It has the best
6 model performance among other prediction models. It has potential utility for risk stratification of
7 the English primary care population and selection of eligible people at high risk for the targeted lung
8 health check programme or lung cancer screening.

9

10 **Keywords:** lung cancer, risk prediction model, screening, early detection, diagnosis, low-dose
11 computerised tomography (LDCT), targeted lung health check (TLHC) programme

1 What is already known on this topic

- 2 • Using risk prediction models to stratify people at the population level and selecting those at the
3 highest risks is an efficient and cost-effective strategy for screening programmes. It avoids
4 waste of resources in screening patients at low risk.
- 5 • An ideal prediction model should have excellent discrimination and calibration in the target
6 population.
- 7 • The Liverpool Lung Project (LLP_{v2}) and the Prostate Lung Colorectal and Ovarian (PLCO_{M2012})
8 models had only moderate discrimination and were not well-calibrated when externally
9 validated using the Clinical Practice Research Datalink (CPRD) data for the English primary care
10 population.

11

12 What this study adds

- 13 • Developed and validated using robust statistical methodologies, the QCancer2 (10-year risk)
14 lung model shows excellent discrimination and calibration in both sexes. It can estimate an
15 individual adult patient's risk for each year of follow-up, for up to 10 years.
- 16 • The QCancer2 (10-year risk) lung model has the best model performance in discrimination and
17 calibration when compared with the other eight models (QCancer (10-year risk), LLP_{v2}, LLP_{v3},
18 LCRAT, PLCO_{M2012}, PLCO_{M2014}, Pittsburgh, and Bach) in three predictive horizons (5/6/10 years)
19 and two sub-populations (smokers and non-smokers aged 40-84 years and ever-smokers aged
20 55-74 years).
- 21 • The QCancer2 (10-year risk) lung model can be applied to the English primary care population to
22 select eligible patients for the Targeted Lung Health Check programme or lung cancer screening
23 using low dose CT.

1 Introduction

2 Lung cancer is a research priority in the UK. It is the third most common cancer in incidence and the
3 most common cause of cancer death in the UK¹. Lung cancer survival in the UK is worse than in other
4 European countries (the EuroCare studies)² and international counterparts (the ICBP studies)^{3,4}.
5 Research evidence from randomised controlled trials (RCTs) has shown that using low dose
6 computerised tomography (LDCT) for lung cancer screening reduces mortality⁵⁻⁷. The United States
7 Preventive Services Task Force (USPSTF) recommended using LDCT for lung cancer screening in
8 2013⁸, and relaxed the eligibility criteria for screening in 2021, by lowering the age threshold from 55
9 to 50 years, and smoking exposure from 30 to 20 pack-years⁹. However, lung cancer screening is still
10 not a routine service in the UK currently. The UK National Screening Committee will meet in June
11 2022 to discuss this issue further.

12

13 NHS England launched a new service, the Targeted Lung Health Check (TLHC), for ever-smokers aged
14 55-74 years registered with a GP in autumn 2019¹⁰. Although this programme is expanding in
15 geographical regions in England, patients outside the participating Clinical Commissioning Groups
16 (CCGs) cannot access this service, which could be a potential issue of health inequality. The TLHC
17 programme uses the Liverpool Lung Project (LLP, version 2)¹¹ and the Prostate, Lung, Colorectal and
18 Ovarian (PLCO_{M2012})¹² cancer screening models to calculate individual patients' risk scores as part of
19 the eligibility criteria. Patients with risk scores higher than the thresholds ($\geq 2.5\%$ in LLP_{v2} or $\geq 1.51\%$
20 in PLCO_{M2012}) are considered at high risk of developing lung cancer and eligible for the TLHC
21 programme. However, O'Dowd et al¹³ externally validated these two models using English primary
22 care datasets (Clinical Practice Research Datalink, CPRD) and concluded that the two models did not
23 have satisfactory discrimination (C statistic ≤ 0.7) and calibration. This raises the question of whether
24 it is suitable to use these two prediction tools to select **eligible participants from the English**
25 **primary care population** for TLHC and lung cancer screening. Even though the LLP_{v2} and PLCO_{M2012}
26 models have been validated, they were developed on highly selected study samples. The LLP model
27 was developed based on patients in Northwest England, where the age-standardised incidence of
28 lung cancer is much higher than other regions of England¹⁴. The PLCO_{M2012} model was developed for
29 the US population. The demographic and clinical characteristics of these study samples may be
30 different from the English primary care population. Therefore, these two models may not be directly
31 applicable to the English primary care population to select eligible participants for lung cancer
32 screening (external validity and limited generalisability). Our team has previously developed and
33 validated the QCancer (10-year risk) algorithms for various cancer sites¹⁵ using electronic health
34 records (EHRs) from the QResearch database. A web calculator is available for public use to calculate

1 an individual's risk of various cancer for up to 10 years, at <https://www.qcancer.org/10yr/male/> (for
2 men) and <https://www.qcancer.org/10yr/female/> (for women).

3
4 In order to provide timely research evidence for the UK National Screening Committee to expedite
5 the decision making for population-based lung cancer screening programmes in the UK, we
6 conducted this study to develop and validate multivariable prognostic models for lung cancer in men
7 and women and compare the model performance of the QCancer2 (10-year risk) lung models
8 against the other models for lung cancer screening, including the LLP_{v2} and PLCO_{M2012} models
9 currently used in the TLHC programme in England.

10

11 [Methods](#)

12 There were two stages in this study. We first updated the QCancer (10-year risk) lung model with
13 more recent data, a larger sample size, and new predictors and validated the model. The second
14 stage was evaluating the model performance of relevant models for lung cancer screening using the
15 same validation dataset with the same criteria and in two patient subgroups (details below). We
16 have published a comprehensive research protocol and statistical analysis plan for the DART-
17 QResearch project¹⁶ before conducting the analyses.

18

19 [Study design, study population, and data source](#)

20 This is a population-based cohort study. We used EHRs from the QResearch® database (version 45)
21 as the data source. The QResearch® database is one of the largest healthcare databases in England,
22 and a trusted research environment accredited by Health Data Research UK. The inclusion and
23 exclusion criteria were similar to those in the previous QCancer (10-year risk) algorithms¹⁵, which
24 allowed us to compare the model performance between the original and the updated versions of
25 models. We included adult patients aged 25-84 years registered with general practices contributing
26 to the QResearch database between 01 January 2005 and 31 March 2020 and excluded patients with
27 a diagnosis of lung cancer before cohort entry. The broad age range covers the majority of the adult
28 primary care population. It also provides great flexibility to select patients in different age groups to
29 evaluate the model performance (Stage 2) or to perform subgroup analysis. The included patients
30 needed to have been registered in the general practices for at least 12 months, and the general
31 practices needed to have contributed to the QResearch database for a minimum of 12 months
32 before the cohort entry date. This was to ensure complete data before cohort entry.

33

1 Primary study outcome

2 The primary study outcome was an incident diagnosis of lung cancer recorded on one or more of the
3 four linked data sources – primary and secondary (hospital episode statistics, HES) care databases,
4 cancer registry (from Public Health England, PHE) and death registry (from the Office for National
5 Statistics, ONS). We used the earliest date on any of the four records as the date of lung cancer
6 diagnosis. We used Read/SNOMED-CT codes to identify events from the GP record, and ICD-10
7 codes to identify events from HES, cancer and death registries.

8 9 Updating the QCancer (10-year risk) lung model

10 The predictors for the original models include age, sex, ethnicity, Townsend scores (a proxy for
11 socioeconomic status), smoking status and intensity, alcohol status, BMI, COPD, asthma, asbestos,
12 prior cancer, and family history of lung cancer. Two additional predictors (pneumonia¹¹ and venous
13 thromboembolism¹⁷) were included in the updated model. We used well-established methodologies
14 for developing and validating the risk prediction algorithms^{15 18}. Three-quarters of general practices
15 were randomly selected for the derivation dataset and the remaining quarter for the validation
16 dataset. Multiple imputation with chained equations was used to replace missing values for
17 ethnicity, body mass index (BMI), alcohol and smoking status, with five imputations. We assumed
18 that the absence of clinical information in the database indicated that the patients did not have
19 specific health conditions, personal or family histories. Therefore, we did not perform multiple
20 imputation for the clinical predictors. We used the imputed values in our main analyses and Rubin's
21 rules to combine the results across the imputed datasets¹⁹.

22
23 Fractional polynomials²⁰ were used to model non-linear relationships between the continuous
24 variables (age, BMI, Townsend scores) and the outcome. Cox proportional hazards models were
25 used to estimate the coefficients for each risk factor for men and women separately, using robust
26 variance estimates to allow for patients clustering within general practices. We initially fitted a full
27 model with all variables for men and women, and retained the variables with a hazard ratio (HR) of
28 <0.91 or >1.10 (for non-continuous variables) for clinical significance and statistical significance at
29 the 0.01 level.

30 31 How the QCancer2 (10-year risk) lung model works

32 We used the coefficients for each predictor from the final Cox regression as weights and combined
33 them with the baseline survivor function evaluated for up to 10 years to derive the risk equations¹⁵.
34 The baseline survivor function was estimated based on the zero values of the centred continuous

1 variables and all binary predictors. The risk equations allow us to derive absolute risk estimates for
2 each year of follow-up, but we had a specific focus on 5-, 6-, and 10-year risk estimates, as we
3 intended to compare the QCancer2 (10-year risk) lung model against other models for lung cancer
4 screening in Stage 2 of this study.

5

6 [Other prediction models for lung cancer screening to be compared against the](#) 7 [QCancer2 \(10-year risk\) lung model](#)

8 Toumazis et al conducted a systematic review of risk prediction models for lung cancer screening²¹.
9 There were also empirical studies comparing some mainstream prediction models published in
10 recent years^{22 23}. We referred to these studies and included models with predictive horizons ≥ 5
11 years, as the purpose of screening is to early detect cancer from asymptomatic populations. The
12 sojourn time for lung cancer progressing from preclinical stage (detectable by screening tests) to
13 clinical stages is 3-6 years, longer in women than in men²⁴. Detecting lung cancer at the earliest
14 possible stage is thought to be most effective in reducing mortality, provided over-diagnosis is
15 avoided. Therefore, prediction models for a longer period are more suitable for screening than those
16 designed for a shorter period (e.g. 1 or 2 years) for diagnostic purposes.

17

18 We included seven models to be compared against our models, including LLP_{v2}, LLP_{v3}, LCRAT,
19 PLCO_{M2012}, PLCO_{M2014}, Pittsburgh, and Bach. The LLP_{v2} and PLCO_{M2012} are used in the TLHC programme
20 to select eligible participants for lung health check. LLP was updated and the newest version (LLP_{v3})
21 was published in 2021¹⁴. The authors recalibrated the intercepts for each age group by sex, while the
22 predictors and their coefficients remained unchanged between LLP_{v2} and LLP_{v3}¹⁴. PLCO_{M2014} was
23 updated based on PLCO_{M2012} and could be used to calculate the risk for never smokers²⁵, while
24 PLCO_{M2012} was developed for ever-smokers only. The 5-year Lung Cancer Risk Assessment Tool
25 (LCRAT)²⁶ was selected because an empirical study concluded that this model performed the best in
26 classifying future lung cancer cases using data from three UK cohorts²³. The 6-year Pittsburgh
27 Predictor²⁷ was included for its simplicity – only 4 predictors in the model (age and three smoking
28 variables), with reasonably predictive accuracy. The PLCO, LCRAT, and Pittsburgh models used either
29 all or part of the PLCO/NLST data in their models. Hence, some study samples overlapped in these
30 models. The Bach model²⁸ can predict 10-year risk, which is the same predictive horizon as our
31 models. Most models were developed based on the US population, except for LLP using regional
32 data from Northwest England. A total of nine prediction models were included in this study. The
33 general information and predictors for each model are summarised in Table 1.

34

1 [Handling EHR data for the variables in other prediction models](#)

2 Due to different study designs (RCT, case-control study, or survey) and different study samples,
3 variables in other prediction models are not necessarily available in EHR. O’Dowd et al. externally
4 validated the LLP_{v2} and PLCO_{M2012} models using CPRD in the English population¹³. We handled most
5 variables in a similar way as reported in their paper, except for ethnicity, the categories of smoking
6 intensity, and the age of starting smoking. Information on patients’ ethnicity is available in the
7 QResearch database. Therefore, we need not assume all patients were white as O’Dowd did. There
8 are five smoking categories in the QResearch database, non-smoker, ex-smoker, light smoker (1-9
9 cigarettes/day), moderate smoker (10-19 cigarettes/day), and heavy smoker (≥ 20 cigarettes/day).
10 We used the median number of cigarettes smoked per day for each category, i.e. 5 for light smokers,
11 15 for moderate smokers, and 30 for heavy smokers for the PLCO and other models, while O’Dowd
12 et al used the lower bound of the number for moderate and heavy smoking, which may
13 underestimate the cumulative lifetime smoking exposure. We assumed people started smoking at 15
14 years, as people aged ≥ 50 years at cohort entry (2005) were born in the 1930s-1950s. People at that
15 time started to smoke at a much younger age and the smoking prevalence was much higher than
16 nowadays²⁹. The current legal age of smoking at 18 was set in 2007. We wrote Stata codes for the
17 QCancer (10-year risk), LLP_{v3}, and PLCO_{M2014} models, while the risk scores for the LLP_{v2}, LCRAT,
18 PLCO_{M2012}, Pittsburgh, and Bach models were calculated using the “lcmmodels” R package.

19

20 [Evaluation of model performance](#)

21 We calculated the absolute predicted risks of individual patients by each algorithm in the validation
22 datasets. We calculated the following measures for discrimination for each algorithm, including the
23 R_D^2 (explained variation, where higher values indicate a greater proportion of variation in time to
24 event is explained by the model)³⁰, the D statistic (where higher values indicate better
25 discrimination)³¹, and Harrell’s C statistic³² (similar to the area under the receiver operating
26 characteristic curve but taking account of the censored nature of cohort data) at the prediction
27 horizon of each algorithm (5, 6 or 10 years). These statistics were combined across the imputed
28 datasets using Rubin’s rules. To assess calibration, we used the “pmcalplot” package in Stata³³ to
29 compare the mean predicted risks (x-axis) against the observed risk (obtained using the Kaplan-
30 Meier estimates, y-axis) in twentieths by sex for each algorithm.

31

32 The three discrimination measures were calculated and calibration plots were made for the updated
33 QCancer2 (10-year risk) lung model for the whole validation cohort (men and women aged 25-84
34 years). In addition, we evaluated the discrimination, calibration, and net benefits of the prediction

1 models in two subgroups – people aged 40-84 years (including non-smokers) as subgroup 1, and
2 ever-smokers aged 55-74 years (the criteria for the TLHC programme)¹⁰ as subgroup 2. There were
3 two main reasons to set these two subgroups. Firstly, the included algorithms were developed with
4 different inclusion and exclusion criteria (such as age range and smoking exposure), these two
5 subgroups broadly cover the inclusion and exclusion criteria for the included algorithms so that they
6 could be compared fairly. Secondly, we aim to provide research evidence regarding which algorithm
7 will be the best to select eligible people for the TLHC programme if rolling out across England
8 (through research evidence from subgroup 2). Decision curve analysis³⁴ was used to evaluate the net
9 benefit of the prediction models (clinical usefulness) for models in three predictive horizons by sex.
10 We calculated the net benefits across a range of threshold probabilities. In general, the model with
11 the highest net benefit at any given risk threshold is considered to have the most clinical value^{35 36}.

12

13 All the analyses were conducted in the QResearch server using Stata 17.0 and R 4.1.0. We used the
14 TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or
15 Diagnosis) statement to guide the conduct and reporting of this study^{37 38}. A TRIPOD checklist for this
16 article is in supplementary table S1.

17

18 [Ethical approval](#)

19 This project was approved by the QResearch Scientific Committee on 8 March 2021. QResearch is a
20 research ethics approved database, confirmed by the East Midlands – Derby Research Ethics
21 Committee (Research ethics reference: 18/EM/0400, project reference: OX37 DART).

22

23 [Patient and public involvement](#)

24 Two lay representatives from the Roy Castle Lung Cancer Foundation were involved in the project
25 set-up phase. They reviewed our lay summary and provided feedback as part of ethical approval for
26 this project. The lay members were not involved in the research process, but we will engage patients
27 and stakeholders in creating accessible materials in lay language for the public to understand
28 prediction models and risk scores of lung cancer and the benefits and harms of the TLHC or lung
29 cancer screening when we disseminate our study findings.

30

31 [Results](#)

32

1 Population characteristics

2 Table 2 shows the baseline demographic and clinical characteristics of the study population and the
3 incident lung cancer cases in the derivation and the validation cohorts for the updated QCancer2
4 (10-year risk) lung model. There were 12,991,042 patients aged 25-84 years in the derivation cohort
5 and 73,380 people developed incident lung cancer during the follow-up period. There were
6 4,137,199 patients in the validation cohort and 22,838 developed incident lung cancer. The ratio of
7 men and women was almost 1:1 in the derivation and validation cohorts, but men had a higher
8 proportion (56%) than women (44%) in the incident lung cancer cases. The mean age for incident
9 lung cancer cases (66 years) was 21 years older than that of the primary care population (45 years) in
10 this study. The Townsend quintile was equally distributed in general in the derivation and validation
11 cohorts, but had a smaller proportion in the two bottom Townsend quintiles (more deprived) in
12 incident lung cancer cases. The percentages of ethnicity, BMI, alcohol, and smoking status recorded
13 in the EHRs in the whole cohort were around 72%, 83%, 82%, and 93%, respectively. The proportions
14 of comorbidities, family history of lung cancer, and any prior cancer at baseline in incident lung
15 cancer cases were much higher than those in the primary care population.

16

17 Comparison of the predictors between the original and the updated QCancer 18 (10-year risk) lung models

19 The hazard ratios (HRs) for the predictors in the original and updated QCancer (10-year risk) lung
20 models are in Table 3. The coefficients for the predictors in the updated models by sex did not
21 change much, compared with those in the original models. Two new predictors in the updated
22 model, pneumonia and venous thromboembolism, were both significant and had higher HRs in
23 women than in men. Other significant predictors included ethnicity, smoking status and intensity,
24 family history of lung cancer, COPD, asthma, prior oral, blood, and renal cancers. Compared with
25 white, other ethnicities had a smaller HR ($HR < 1$), except that Bangladeshi and Chinese women had
26 an $HR > 1$. The HR increased with the current smoking status and smoking intensity (cigarette per day)
27 and was generally in a dose-response relationship in both sexes. The HR for moderate smokers (10-
28 19 cigarettes/day) was smaller than that in light smokers (1-9 cigarettes/day) in men. Two smoking-
29 related conditions, COPD and prior oral cancer, had an $HR > 2$ in both sexes. Asbestos exposure, prior
30 colorectal and gastric-oesophageal cancers, and drinking status, were all significant in men, but not
31 significant in women. Such differences showed the importance of developing models separately by
32 sex, as men and women may have different significant predictors. Even for the same predictors, the
33 coefficients and the association between predictors and the outcome could be different between
34 the sexes.

1
2 Supplementary Figure S1 shows the non-linear relationship (fractional polynomials) between the
3 continuous variables (age, BMI, Townsend score) and the outcome (incident lung cancer cases) by
4 sex. Supplementary Figure S2 shows the non-linear relationship between the interaction terms (age
5 and smoking status) and the outcome by sex.

7 Evaluating the model performance for prediction models for lung cancer 8 screening

9 The prediction models being compared and evaluated are summarised in supplementary table S2.
10 The descriptive statistics of the predicted risks for each model in the two subgroup populations in
11 three predictive horizons by sex are in supplementary tables S3 and S4.

12

13 **Discrimination**

14 Results for the three discrimination measures (Harrell's C, D statistics, and R_D^2) for the original and
15 updated QCancer (10-year risk) lung models in patients aged 25-84 years are shown in Table 4. The
16 three discrimination statistics were slightly improved in the updated model. The updated QCancer2
17 (10-year risk) lung model explained 65% of the variation in time to diagnosis of lung cancer. The D
18 statistic was around 2.80 and the C statistic was around 0.9 (indicating excellent discrimination) in
19 men and women.

20

21 The discrimination statistics for patient subgroup 1 (smokers and non-smokers aged 40-84 years)
22 and subgroup 2 (ever-smokers aged 55-74 years) are in Tables 5 and 6, respectively, reported by sex
23 and predictive horizons. In each patient subgroup, the QCancer2 (10-year risk) lung cancer model
24 had the highest values for all three discrimination statistics across three predictive horizons (5/6/10
25 years) when compared with other prediction models. For other prediction models, in the 5-year
26 horizon, LLP_{v3} had slightly higher Harrell's C statistics than LLP_{v2} and LCRAT in patient subgroup 1, but
27 comparable D statistics and R_D^2 in the two patient subgroups for both sexes. In the 6-year horizon,
28 PLCO_{M2014} had the highest Harrell's C, but the Pittsburgh predictor had the highest D statistic and R_D^2
29 in patient subgroup 1. PLCO_{M2014} consistently had the highest statistics in patient subgroup 2. In the
30 10-year horizon, the QCancer2 (10-year risk) lung model out-performed the Bach model. Through a
31 comprehensive model evaluation (by sex, different age groups, and smoking exposure), we found
32 that the three discrimination measures were often different between sexes and there was no
33 consistent pattern of higher statistics in men or women. This again demonstrates the importance of

1 model evaluation in different patient subgroups and sexes, rather than pooling the data together for
2 a single summarised statistic.

3

4 **Calibration**

5 Calibration plots are presented in Figures 1-3. Figure 1 is the updated QCancer2 (10-year risk) lung
6 model in three predictive horizons by sex. Figures 2 and 3 are calibration plots for the two patient
7 subgroups. The QCancer2 (10-year risk) lung model was generally well-calibrated across different
8 risk levels in both sexes, in three predictive horizons, in the whole validation cohort and the two
9 subgroups. For the other prediction models, in the 5-year horizon, a common problem for the LLP_{v2},
10 LLP_{v3}, and LCRAT models in patient subgroup 2 (ever-smokers aged 55-74 years) was overestimation
11 (the predicted risks were much greater than the observed risks) in both sexes, especially at higher
12 risk bands. Calibration of these three models was better in patient subgroup 1, but still
13 overestimated the risk at high-risk levels. Compared with LLP_{v2}, LLP_{v3} was better calibrated in both
14 patient subgroups. In the 6-year horizon, the PLCO_{M2012} severely under-estimated at low-risk
15 thresholds and over-estimated at high-risk thresholds, particularly in patient subgroup 2. PLCO_{M2014}
16 under-estimated across all risk bands in both sexes and both patient subgroups, while the Pittsburgh
17 predictor over-estimated the risk. The Bach model was poorly calibrated in both sexes, particularly in
18 patient subgroup 2.

19

20 **Decision curve analysis**

21 Figures 4-5 show the net benefit curves for the prediction models in the two subgroups by sex in
22 three predictive horizons. The QCancer2 (10-year risk) lung model had the highest net benefit,
23 compared with other prediction models and strategies considering either no patients or all patients
24 for intervention across a range of risk thresholds.

25

26 Discussion

27

28 Principal findings

29 In this study, we developed and validated the QCancer2 (10-year risk) lung model with more recent
30 data and a larger sample size to quantify the future risk of men and women being diagnosed with
31 lung cancer in the next 10 years. The predictors include sociodemographic characteristics, lifestyle,
32 comorbidities, family history and personal history of other cancers. The updated model performed
33 slightly better than the original version. We compared the QCancer2 (10-year risk) lung model
34 against other prediction models and found that the QCancer2 (10-year risk) lung model had the best

1 performance in discrimination, calibration, and net benefits in two subgroups across three predictive
2 horizons.

3

4 [Comparison with existing literature](#)

5 The QCancer (10-year risk) models are **prognostic** models, which can estimate an individual patient's
6 **future** risk of cancer while the patient has not yet presented any symptoms. Prognostic models are
7 more suitable for early detection of cancer through screening in asymptomatic populations, while
8 diagnostic models (known as QCancer) aim to predict the risks of existing cancer in patients already
9 present with symptoms that may indicate cancer.

10

11 Compared with the original model using a total of 6.6 million patients aged 25-84 years and 13,570
12 incident lung cancer cases from 753 practices from 1 January 1998 to 30 September 2013 in the
13 deviation and validation cohorts, the sample size of the whole population and the incidence lung
14 cancer cases in the updated model increased substantially, due to the expansion of the QResearch
15 database in recent years. We have conducted a more thorough assessment of model performance in
16 this study. ten Haaf et al. mentioned little attention has been given to sex-specific risk-stratification
17 in current practice³⁹. We developed and validated our models by sex and found that the predictors
18 differed between men and women. Even for the same predictors, their coefficients may be different.
19 The histological subtypes and preclinical duration of lung cancer may vary between sexes^{24 39}. It may
20 need to consider sex-specific risk thresholds and screening intervals for lung cancer screening.

21

22 When choosing risk prediction models for population-based screening programmes, we need to
23 consider whether the models can be applied to the targeted population (external validity and
24 generalisability), as models may be developed using a specific study sample, with limitations in study
25 design, data, or internal validity of the study findings. Some models may be developed using highly
26 selective study samples or populations, whose baseline risk was higher than the general population.
27 The LLP model had limitations in study design and study sample (case-control study using regional
28 data)¹¹. The PLCO_{M2012} model was developed using data from the US population¹². When externally
29 validating these two models using CPRD, O'Dowd found that both models underestimated the risk in
30 patients at low predicted risk (observed risk > predicted risk) but overestimated the risk in patients at
31 higher risk (observed risk < predicted risk, cut-offs at around 1% for both models)¹³. The C statistics
32 (equivalent to AUC in O'Dowd's report) in this study were even lower. Possible explanations included
33 study sample selection (two patient subgroups in this study vs ever-smokers aged 50-80 years),
34 availability of information, population and geographical coverage in different EHR databases

1 (QResearch vs CPRD), different ways of handling the variables unavailable from the EHR database
2 (described in the methods section), sample size and study period (this study had a larger sample size
3 and a longer study period). Despite these differences, both studies reached the same conclusion that
4 the LLP_{v2} and PLCO_{M2012} models did not have satisfactory discrimination and were not well-calibrated
5 when externally validated using different English primary care databases. They may not be directly
6 applicable to the English primary care population.

7
8 Robbins et al. evaluated the model performance of lung cancer risk models (LLP_{v2}, LLP_{v3}, LCRAT,
9 LCDRAT, PLCO_{m2012}, and Bach) in current and former smokers aged 40-80 years using three UK
10 cohorts (UK Biobank, EPIC-UK, and Generations Study) to define the eligibility for lung cancer
11 screening²³. We did not include LCDRAT in our study, as this model predicts lung cancer death. The
12 AUC values for the models in the two patient subgroups (patients aged 40-74 years and 55-74 years,
13 0.73-0.82) were much higher in the three cohorts than those in our study. For calibration, all models
14 overestimated risk in all cohorts. The ratio of expected vs observed (E:O) was between 1.20 (LLP_{v3})
15 and 2.25 (LLP_{v2}). We found both overestimation and underestimation appeared in our study
16 samples. Robbins et al. emphasised the importance of validating prediction tools in specific
17 countries. We agreed with this point.

18

19 [Strengths and limitations of this study](#)

20 **Strengths**

21 Informed by the existing research evidence and clinical expertise, we included as many relevant
22 predictors as possible when we updated the QCancer2 (10-year risk) lung model. Using
23 contemporaneous primary care EHRs to develop and validate risk prediction models is likely to have
24 great face validity, generalisability, and applicability to the whole primary care population, compared
25 with study designs like RCT or survey, or data from other countries (like the US). EHRs in the UK have
26 a high level of accuracy and completeness of sociodemographic information and clinical diagnoses.
27 Clinical and diagnostic information recorded by healthcare professionals should be more accurate
28 than collecting such information from patients using surveys or interviews. Therefore, it can reduce
29 information and recall bias. In addition, our study also benefits from a large sample size and a long
30 duration of follow-up. The population in the QResearch database is representative of the whole
31 English primary care population, in terms of age, sex, ethnicity, socioeconomic deprivation, smoking
32 exposure, and geographical coverage. Therefore, it minimises selection and respondent bias. The
33 QCancer2 (10-year risk) lung model could be applied to the whole English primary care population.

34

1 We would like to consider our QCancer2 (10-year risk) lung models as inclusive algorithms. They
2 were designed for the adult primary care population with a wide age range (25-84 years) and various
3 smoking statuses (non-, current, or ex-smokers). They are “live” and flexible risk prediction models,
4 which can be updated based on the previous version with more recent data, as the population
5 changes over time. Physicians and the public can use our models to calculate and understand an
6 individual’s risk of developing lung cancer for each year of follow-up, for up to 10 years, which is
7 more flexible than models predicting a fixed predictive horizon such as 5-year for LLP and 6-year for
8 PLCO. The QCancer2 (10-year risk) lung models were developed and validated in men and women
9 separately, with some different predictors in the men and women models. Therefore, the models
10 allow sex-specific risk stratification. Compared with other models, this is a unique strength. The fact
11 that the QCancer2 (10-year risk) lung models outperform other prediction models in the ever-
12 smokers aged 55-74 years (subgroup 2) demonstrates that our model is robust and suitable for
13 selecting eligible patients for lung cancer screening. This bonus point makes our models more
14 attractive for clinical application and improving population health.

15

16 Finally, we pre-registered the research protocol and statistical analysis plan in the public domain. We
17 used robust and advanced statistical methods and followed the recommendations of the TRIPOD
18 guidelines when we developed and validated our models and reported the study findings.

19

20 **Limitations**

21 Smoking is a strong predictor of lung cancer. When primary care providers ask the smoking status
22 and intensity, some patients may feel ashamed and under-report their smoking intensity than their
23 actual situation. This could affect the accurate estimation of the association between smoking
24 exposure and lung cancer. But there is little that researchers could do about this. Family history of
25 cancer may have been recorded opportunistically rather than systematically in the EHR. Patients
26 with a family member diagnosed with cancer may be more likely to report this to their GPs and for
27 this to be recorded, which would cause information bias. Not all relevant information in other
28 prediction models is available from EHRs. Therefore, we needed to make reasonable assumptions
29 and adapt the situation for the EHR in the English population when we calculated the risk scores
30 using other prediction models. If we could not find values from reliable sources or references, we
31 used the median values or categories, as O’Dowd et al¹³ did in their study. The unavailable
32 information and the way we handled the variables may inaccurately estimate the risk scores for
33 individual patients in other prediction models, which could either overestimate or underestimate
34 the risk. This may consequently influence the evaluation of model performance for individual

1 models. Another limitation is that we did not use external data to validate QCancer (10-year risk)
2 lung models. It is possible to use another data source (e.g. CPRD) and the internal-external cross-
3 validation approach⁴⁰ to externally validate our model in future studies, subject to funding
4 availability.

5

6 [Implications for practice and health policy](#)

7 As a universal service with a very high population coverage in the UK, primary care has great
8 potential and opportunity for early detection and diagnosis of cancer, and GPs could be strong
9 advocates for the TLHC programme and lung cancer screening. We have demonstrated the model
10 performance in the QCancer2 (10-year risk) lung model. More accurate risk estimation has an impact
11 on risk stratification at the population level and risk communication with the patients. The
12 implementation of the QCancer2 (10-year risk) lung model in primary care computer systems could
13 facilitate patient-GP discussion about the risks and benefits of preventive interventions for individual
14 patients. This could improve patients' awareness of their health status and risk level, which in turn
15 might increase their willingness to participate in the TLHC programme or lead to behavioural
16 changes such as considering smoking cessation.

17

18 The updated QCancer2 (10-year risk) lung model allows batch-mode processes that use existing
19 information in EHRs at each practice to facilitate the selection of eligible patients at high risk for the
20 TLHC programme or lung cancer screening. Compared with using questionnaires to collect
21 information from individual patients and calculating risk scores to check their eligibility, the batch-
22 mode process is more efficient. It can stratify the primary care population based on risk level for
23 better target in prevention or screening programmes. It can not only substantially reduce human
24 resources and costs, but also save time and streamline the administrative process for better patient
25 experience and increased patient satisfaction.

26

27 We comprehensively compared nine prediction models using the same validation dataset in this
28 study. We evaluated model performance in two patient subgroups, which broadly covered the
29 inclusion and exclusion criteria of the study sample in each model and the eligibility criteria for the
30 TLHC programme. The LLP_{v2} and PLCO_{M2012} may not be the best models to select eligible primary care
31 patients for the TLHC programme, due to their unsatisfactory model performance in patient
32 subgroup 2. Through such a thorough assessment in this study, we provide research evidence to
33 assist policymakers in considering the age range and smoking exposure for lung cancer screening
34 and increase equality in health services access. In the end, more patients can be diagnosed at earlier

1 stages and through screening-detected route, which can lead to better survival outcomes and
2 reduced lung cancer mortality in the UK. Considering the sizable incidence and mortality of lung
3 cancer at the population level, the improvement in lung cancer could substantially contribute to the
4 UK government's ambition that 75% of people with cancer will be diagnosed at early stages by
5 2028⁴¹. Meanwhile, patients may benefit from primary or secondary prevention of other
6 cardiorespiratory diseases through participating in the TLHC programme. We do not recommend a
7 risk threshold for our models for lung cancer screening, as this needs to consider the balance
8 between benefits and harms, cost-efficiency, health resources, accessibility and health equality, and
9 the potential impact of the screening program at the population level. Our colleagues in another
10 strand of our work package will conduct a separate study to evaluate the cost-effectiveness and
11 determine the risk thresholds for lung cancer screening in England.

12

13 Conclusion

14 Developed, updated, and validated using primary care EHRs, the QCancer2 (10-year risk) lung model
15 is robust and flexible. It can estimate an individual adult patient's risk of lung cancer diagnosis during
16 each year of follow-up, for up to 10 years. It has the best performance among other prediction
17 models for lung cancer screening in discrimination and calibration for both sexes across three
18 predictive horizons (5/6/10 years). It also has the highest net benefit. The QCancer2 (10-year risk)
19 lung model is more suitable for selecting patients at high risk from the English primary care
20 population for lung cancer screening using LDCT than the currently used LLP_{v2} and PLCO_{M2012} models
21 in the TLHC programme.

1 Declarations

2 WL and JH-C have full access to all data in this study and take the responsibility for the integrity of
3 the data and the accuracy of data analysis. To guarantee the confidentiality of personal and health
4 information of patients, only the named authors have had full access to the data during the study, in
5 accordance with the relevant licence agreements. Information on access to the QResearch data is
6 available on the QResearch website (www.qresearch.org).

7
8 JH-C is the guarantor for the study and affirms that the manuscript resulting from this work is an
9 honest, accurate, and transparent account of the study being reported; that no important aspects of
10 the study are omitted; and that any discrepancies from the study protocol and statistical analysis
11 plan¹⁶ have been explained.

13 Authors' contributions and consent for publication

14 FG and JH-C secured the funding. FG is the chief investigator of the DART project, and JH-C is the
15 joint package lead (WP6 – Primary care, population health, and health economics). JH-C and WL
16 contributed to the study conceptualisation. WL specified the data and led on the ethical approval.
17 WL designed the statistical analysis plan and drafted the whole research protocol and statistical
18 analysis plan, with methodological input from JH-C and CC, and clinical and contextual input from JH-
19 C, DB, FG, and JB. WL and JH-C wrote the codes and performed the analyses. CC had substantial
20 contributions to the statistical methodology. WL drafted the whole paper. All authors contributed to
21 the interpretation of the results and revision of the manuscript, and approved the final version of
22 the manuscript for publication.

24 Funding

25 The DART project is funded by Innovate UK (UK Research and Innovation, grant reference: 40255).
26 QResearch received funding from the NIHR Biomedical Research Centre, Oxford, grants from John
27 Fell Oxford University Press Research Fund, grants from Cancer Research UK (Grant number
28 C5255/A18085), through the Cancer Research UK Oxford Centre, grants from the Oxford Wellcome
29 Institutional Strategic Support Fund (204826/Z/16/Z), during the conduct of the study.

31 Acknowledgements

32 We thank the two lay members from the Roy Castle Lung Cancer Foundation who reviewed our lay
33 summary of the DART-QResearch Project for ethical approval and provided very helpful feedback.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

We acknowledge the contribution of the patients and the general practices who contribute to QResearch® and EMIS (Egton Medical Information Systems) Health and the Chancellor Masters & Scholars of the University of Oxford for expertise in establishing, developing and supporting the QResearch database. The Hospital Episode Statistics data used in this analysis are Copyright © (2022) to the Health and Social Care Information Centre and re-used with the permission of the Health and Social Care Information Centre and the University of Oxford. All rights reserved. This project involves data derived from patient-level information collected by the NHS, as part of the care and support of cancer patients. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE). Access to the data was facilitated by the PHE Office for Data Release. The death registration data are provided by the Office for National Statistics. NHS Digital, Public Health England, and the Office of National Statistics bear no responsibility for the analysis or interpretation of the data.

The views expressed in this manuscript are those of the authors. None of the acknowledged organisations or funding bodies has been involved in any research process, including study design, data specification, statistical analysis, interpretation of results, preparing manuscripts, or decision to publish.

Study and authors' information

Project website: www.dartlunghealth.co.uk

ORCID

Weiqi Liao, <http://orcid.org/0000-0002-8605-3749>

Judith Burchardt, <http://orcid.org/0000-0002-2251-0023>

Julia Hippisley-Cox, <http://orcid.org/0000-0002-2479-7283>

Twitter:

@dartlunghealth (the DART project),
@WLiao_Ox (Weiqi Liao),
@JudithBurchardt (Judith Burchardt),
@JuliaHCox (Julia Hippisley-Cox)

1 Declaration of interests

- 2 All authors have completed the ICMJE uniform disclosure form.
- 3 JH-C is an unpaid director of QResearch, a not-for-profit organisation in a partnership between the
- 4 University of Oxford and EMIS Health, who supply the QResearch database for this work. JHC is a
- 5 founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019. ClinRisk Ltd
- 6 produces open and closed source software to implement clinical risk algorithms into clinical
- 7 computer systems including the original QCancer algorithms referred to above. Other authors have
- 8 no interests to declare for this submitted work.

References

1. Cancer Research UK. Lung cancer statistics 2021 [updated 5 April 2021. Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer>.
2. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE-5—a population-based study. *The Lancet Oncology* 2014;15(1):23-34. doi: 10.1016/s1470-2045(13)70546-1
3. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *The Lancet* 2011;377(9760):127-38. doi: 10.1016/s0140-6736(10)62231-3
4. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. *Thorax* 2013;68(6):551-64. doi: 10.1136/thoraxjnl-2012-202297
5. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365(5):395-409. doi: 10.1056/NEJMoa1102873 [published Online First: 2011/07/01]
6. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. *N Engl J Med* 2020;382(6):503-13. doi: 10.1056/NEJMoa1911793 [published Online First: 2020/01/30]
7. Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. *Lancet Reg Health Eur* 2021;10:100179. doi: 10.1016/j.lanep.2021.100179 [published Online First: 2021/11/23]
8. Moyer VA, U. S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160(5):330-8. doi: 10.7326/M13-2771 [published Online First: 2014/01/01]
9. Krist AH, Davidson KW, Mangione CM, et al. Screening for Lung Cancer. *JAMA* 2021;325(10) doi: 10.1001/jama.2021.1117
10. Cancer Research UK. Lung Health Checks 2021 [Available from: <https://www.cancerresearchuk.org/about-cancer/lung-cancer/getting-diagnosed/lung-health-checks> accessed 5 April 2021.
11. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. *Br J Cancer* 2008;98(2):270-6. doi: 10.1038/sj.bjc.6604158 [published Online First: 2007/12/19]
12. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. *N Engl J Med* 2013;368(8):728-36. doi: 10.1056/NEJMoa1211776 [published Online First: 2013/02/22]
13. O'Dowd EL, Ten Haaf K, Kaur J, et al. Selection of eligible participants for screening for lung cancer using primary care data. *Thorax* 2021 doi: 10.1136/thoraxjnl-2021-217142 [published Online First: 2021/10/31]
14. Field JK, Vulkan D, Davies MPA, et al. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. *Thorax* 2021;76(2):161-68. doi: 10.1136/thoraxjnl-2020-215158 [published Online First: 2020/10/22]
15. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. *BMJ Open* 2015;5(3):e007825. doi: 10.1136/bmjopen-2015-007825
16. Liao W, Burchardt J, Coupland C, et al. Development, validation, and evaluation of prediction models to identify individuals at high risk of lung cancer for screening in the English primary

- care population using the QResearch® database: research protocol and statistical analysis plan. *medRxiv* 2022 doi: 10.1101/2022.01.07.22268789 [published Online First: 07 Jan 2022]
17. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. *Br J Cancer* 2004;91(1):92-5. doi: 10.1038/sj.bjc.6601964 [published Online First: 2004/07/01]
 18. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ* 2017;357:j2099. doi: 10.1136/bmj.j2099 [published Online First: 2017/05/26]
 19. Rubin DB. Multiple Imputation for Non-response in Surveys. New York: John Wiley 1987.
 20. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. *Int J Epidemiol* 1999;28(5):964-74. doi: 10.1093/ije/28.5.964 [published Online First: 1999/12/22]
 21. Toumazis I, Bastani M, Han SS, et al. Risk-Based lung cancer screening: A systematic review. *Lung Cancer* 2020;147:154-86. doi: 10.1016/j.lungcan.2020.07.007 [published Online First: 2020/07/30]
 22. Ten Haaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. *PLoS Med* 2017;14(4):e1002277. doi: 10.1371/journal.pmed.1002277 [published Online First: 2017/04/05]
 23. Robbins HA, Alcala K, Swerdlow AJ, et al. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom. *Br J Cancer* 2021;124(12):2026-34. doi: 10.1038/s41416-021-01278-0 [published Online First: 2021/04/14]
 24. Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. *Cancer Epidemiol Biomarkers Prev* 2015;24(1):154-61. doi: 10.1158/1055-9965.EPI-14-0745 [published Online First: 2014/10/15]
 25. Tammemägi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med* 2014;11(12):e1001764. doi: 10.1371/journal.pmed.1001764 [published Online First: 2014/12/03]
 26. Katki HA, Kovalchik SA, Berg CD, et al. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. *JAMA* 2016;315(21):2300-11. doi: 10.1001/jama.2016.6255 [published Online First: 2016/05/18]
 27. Wilson DO, Weissfeld J. A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor. *Lung Cancer* 2015;89(1):31-7. doi: 10.1016/j.lungcan.2015.03.021 [published Online First: 2015/04/13]
 28. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J Natl Cancer Inst* 2003;95(6):470-8. doi: 10.1093/jnci/95.6.470 [published Online First: 2003/03/20]
 29. Wald NJ. UK smoking statistics. Oxford: Oxford University Press 1988.
 30. Royston P. Explained variation for survival models. *Stata J* 2006;6:1-14.
 31. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. *Stat Med* 2004;23:723-48.
 32. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers' D. *Stata Journal* 2010;10(3):339-58.
 33. Ensor J, Snell KI, Martin EC. PMCALPLOT: Stata module to produce calibration plot of prediction model performance. Statistical Software Components S458486. Boston College Department of Economics, 2018.
 34. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;26(6):565-74. doi: 10.1177/0272989X06295361 [published Online First: 2006/11/14]

35. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. *BMJ* 2016;352:i6. doi: 10.1136/bmj.i6 [published Online First: 2016/01/27]
36. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. *Diagn Progn Res* 2019;3:18. doi: 10.1186/s41512-019-0064-7 [published Online First: 2019/10/09]
37. Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD StatementThe TRIPOD Statement. *Annals of Internal Medicine* 2015;162(1):55-63. doi: 10.7326/M14-0697
38. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162(1):W1-73. doi: 10.7326/M14-0698 [published Online First: 2015/01/07]
39. Ten Haaf K, van der Aalst CM, de Koning HJ, et al. Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges. *Int J Cancer* 2021;149(2):250-63. doi: 10.1002/ijc.33578 [published Online First: 2021/03/31]
40. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and external validation. *J Clin Epidemiol* 2016;69:245-7. doi: 10.1016/j.jclinepi.2015.04.005 [published Online First: 2015/05/20]
41. NHS England. NHS Long Term Plan ambitions for cancer [Available from: <https://www.england.nhs.uk/cancer/strategy/> accessed 6 September 2021.

Tables

Table 1 – Summary of predictors in the QCancer2 (10-year risk) lung model and other prediction models

Prediction models	QCancer2 (10-year) lung model	LLP	LCRAT	PLCO	Pittsburgh	Bach
Model versions	original and updated	v2, v3		2012, 2014		
Reference	[15]	[11, 14]	[26]	[12, 25]	[27]	[28]
Predictive horizon	Up to 10 years	5 years	5 years	6 years	6 years	Up to 10 years
Include never-smokers	√	√		√ (2014 only)		
Predictors						
Age	√	√	√	√	√	√
Age range (years old)	25-84	40-84	55-80	55-74	50-79	45-69
Sex	√	√	√			√
Education			√	√		
Race/Ethnicity	√		√	√		
Socioeconomic status (Townsend score)	√					
Smoking status	√			√	√	
Smoking duration (years smoked)		√	√	√	√	√
Smoking intensity (cigarette per day)	√		√	√	√	√
Years quit smoking				√		√
Pack-years			√			
Alcohol	√					
BMI	√		√	√		
COPD	√		√	√		
Personal history of cancer	√	√		√		
Family history of lung cancer	√	√	√	√		
History of pneumonia	*	√				
Asbestos exposure	√	√				√
Asthma	√					

Venous thromboembolism

✱

✱ New in the QCancer2 model

Abbreviations: LLP – Liverpool Lung Project (England), LCRAT – Lung Cancer Risk Assessment Tool (US), PLCO – the Prostate, Lung, Colorectal, and Ovarian Cancer Screening programme (US)

Notes:

1. Age, BMI, and Townsend scores were operated as continuous variables in both QCancer (10-year risk lung) models. Fractional polynomial was used to fit their non-linear relationship with the outcome (two fractional polynomial terms).
2. COPD includes bronchitis and emphysema in the QCancer models.

Table 2 – Baseline demographic and clinical characteristics of the derivation and validation cohort for the updated QCancer2 (10-year risk) model

	All population		Incident lung cancer cases	
	Derivation	Validation	Derivation	Validation
Sample size (N)	12991042	4137199	73380	22838
Male sex, n (%)	6476207 (49.9)	2059175 (49.8)	41003 (55.9)	12768 (55.9)
Age, mean (SD)	45.0 (15.6)	45.2 (15.6)	65.8 (10.4)	66.0 (10.4)
Age groups				
25-29 years	2307317 (17.8)	718752 (17.4)	122 (0.2)	24 (0.1)
30-34 years	2002174 (15.4)	628639 (15.2)	261 (0.4)	80 (0.4)
35-39 years	1618962 (12.5)	517697 (12.5)	652 (0.9)	189 (0.8)
40-44 years	1358535 (10.5)	436425 (10.5)	1421 (1.9)	479 (2.1)
45-49 years	1159196 (8.9)	369609 (8.9)	2908 (4.0)	895 (3.9)
50-54 years	996141 (7.7)	318840 (7.7)	5212 (7.1)	1562 (6.8)
55-59 years	913302 (7.0)	294035 (7.1)	8956 (12.2)	2681 (11.7)
60-64 years	753825 (5.8)	242618 (5.9)	11276 (15.4)	3466 (15.2)
65-69 years	637454 (4.9)	204891 (5.0)	12966 (17.7)	4101 (18.0)
70-74 years	524814 (4.0)	169382 (4.1)	12710 (17.3)	3959 (17.3)
75-79 years	431758 (3.3)	140891 (3.4)	10927 (14.9)	3452 (15.1)
80-84 years	287564 (2.2)	95420 (2.3)	5969 (8.1)	1950 (8.5)
Townsend score, mean (SD)	0.6 (3.2)	0.4 (3.2)	0.4 (3.1)	0.3 (3.1)
Townsend quintile, n (%)				
Most affluent quintile (Q1)	2830215 (21.8)	928894 (22.5)	16164 (22.0)	5128 (22.5)
Quintile 2	2651740 (20.4)	869971 (21.0)	16110 (22.0)	4939 (21.6)
Quintile 3	2513467 (19.3)	823887 (19.9)	15511 (21.1)	4976 (21.8)
Quintile 4	2447443 (18.8)	777626 (18.8)	14042 (19.1)	4212 (18.4)
Most deprived quintile (Q5)	2548177 (19.6)	736821 (17.8)	11553 (15.7)	3583 (15.7)
Ethnicity recorded, n (%)				
White	7481059 (57.6)	2365041 (57.2)	48418 (66.0)	15405 (67.5)
Indian	337885 (2.6)	121854 (2.9)	359 (0.5)	121 (0.5)
Pakistani	198742 (1.5)	61207 (1.5)	273 (0.4)	69 (0.3)
Bangladeshi	138942 (1.1)	35258 (0.9)	344 (0.5)	72 (0.3)
Other Asian	220406 (1.7)	74806 (1.8)	227 (0.3)	84 (0.4)
Caribbean	138224 (1.1)	42853 (1.0)	559 (0.8)	183 (0.8)
Black African	323946 (2.5)	99629 (2.4)	226 (0.3)	59 (0.3)
Chinese	104082 (0.8)	27714 (0.7)	108 (0.1)	47 (0.2)
Other	437780 (3.4)	135417 (3.3)	540 (0.7)	160 (0.7)
BMI recorded, n (%)	10797197 (83.1)	3459976 (83.6)	66190 (90.2)	20841 (91.3)

BMI, mean (SD)	26.5 (5.3)	26.4 (5.2)	26.4 (5.1)	26.4 (5.0)
Smoking status recorded, n (%)				
Smoking status recorded, n (%)	12119036 (93.3)	3868125 (93.5)	70739 (96.4)	22171 (97.1)
Non-smoker	6851842 (52.7)	2208409 (53.4)	14352 (19.6)	4859 (21.3)
Ex-smoker	2389705 (18.4)	756862 (18.3)	21909 (29.9)	6671 (29.2)
Light smoker (1-9 cigarettes/day)	2150683 (16.6)	673258 (16.3)	24810 (33.8)	7688 (33.7)
Moderate smoker (10-19 cigarettes/day)	465255 (3.6)	146132 (3.5)	5150 (7.0)	1547 (6.8)
Heavy smoker (≥ 20 cigarettes/day)	261551 (2.0)	83464 (2.0)	4518 (6.2)	1406 (6.2)
Alcohol status recorded, n (%)				
Alcohol status recorded, n (%)	10531942 (81.1)	3438730 (83.1)	65272 (89.0)	20649 (90.4)
Non-drinker	6591000 (50.7)	2163345 (52.3)	41780 (56.9)	13126 (57.5)
Trivial (<1 unit/day)	2013473 (15.5)	658992 (15.9)	10364 (14.1)	3260 (14.3)
Light (1-2 units/day)	996128 (7.7)	312150 (7.5)	5340 (7.3)	1733 (7.6)
Moderate (3-6 units/day)	801199 (6.2)	263899 (6.4)	6467 (8.8)	2059 (9.0)
Heavy (7-9 units/day)	63064 (0.5)	20415 (0.5)	805 (1.1)	314 (1.4)
Very Heavy (>9 units/day)	55131 (0.4)	16032 (0.4)	395 (0.5)	118 (0.5)
Amount not recorded	11947 (0.1)	3897 (0.1)	121 (0.2)	39 (0.2)
Comorbidities, n (%)				
Any lung disease (COPD, asthma, TB, pneumonia)	1623152 (12.5)	519999 (12.6)	16937 (23.1)	5336 (23.4)
COPD	182746 (1.4)	57823 (1.4)	9686 (13.2)	2995 (13.1)
Asthma	1295982 (10.0)	415159 (10.0)	7976 (10.9)	2493 (10.9)
Pneumonia	185790 (1.4)	58429 (1.4)	2347 (3.2)	735 (3.2)
Tuberculosis (TB)	92141 (0.7)	30683 (0.7)	1163 (1.6)	404 (1.8)
Bronchiectasis	30970 (0.2)	9998 (0.2)	467 (0.6)	143 (0.6)
Asbestos exposure or asbestosis	12714 (0.1)	4034 (0.1)	377 (0.5)	127 (0.6)
Hypertension	1505956 (11.6)	488787 (11.8)	23293 (31.7)	7447 (32.6)
Venous thromboembolism	144720 (1.1)	46325 (1.1)	1943 (2.6)	639 (2.8)
Any cancer recorded at baseline				
Any cancer recorded at baseline	299771 (2.3)	97506 (2.4)	5559 (7.6)	1862 (8.2)
Blood cancer	37301 (0.3)	11969 (0.3)	640 (0.9)	197 (0.9)
Breast cancer	87142 (0.7)	28764 (0.7)	1470 (2.0)	495 (2.2)
Cervical cancer	9026 (0.1)	2944 (0.1)	184 (0.3)	66 (0.3)
Oral cancer	6004 (0.0)	1951 (0.0)	211 (0.3)	81 (0.4)
Ovarian cancer	7397 (0.1)	2369 (0.1)	85 (0.1)	23 (0.1)
Renal cancer	20290 (0.2)	6391 (0.2)	623 (0.8)	208 (0.9)
Uterine cancer	7938 (0.1)	2571 (0.1)	119 (0.2)	46 (0.2)
Family history of lung cancer				
Family history of lung cancer	83557 (0.6)	28929 (0.7)	730 (1.0)	286 (1.3)
Family history of any cancer				
Family history of any cancer	1436332 (11.1)	460819 (11.1)	6368 (8.7)	2178 (9.5)

Table 3 – Hazard ratios for the predictors in the original and updated QCancer (10-year risk) lung models

Predictors	Men		Women	
	QCancer2 (2022)†	Original (2015)	QCancer2 (2022)†	Original (2015)
White	Reference category			
Indian	.504 (.439 to .58)	.503 (.438 to .578)	.676 (.58 to .788)	.674 (.579 to .786)
Pakistani	.597 (.515 to .691)	.595 (.514 to .689)	.718 (.554 to .931)	.717 (.553 to .929)
Bangladeshi	.856 (.747 to .98)	.853 (.746 to .977)	1.04 (.827 to 1.32)	1.04 (.824 to 1.31)
Other Asian	.564 (.464 to .685)	.563 (.463 to .684)	.751 (.586 to .962)	.749 (.585 to .959)
Caribbean	.685 (.627 to .749)	.684 (.626 to .747)	.664 (.583 to .757)	.663 (.582 to .755)
Black African	.526 (.429 to .644)	.525 (.429 to .643)	.689 (.556 to .853)	.687 (.555 to .851)
Chinese	.590 (.462 to .754)	.588 (.460 to .751)	1.19 (.93 to 1.51)	1.18 (.926 to 1.5)
Other ethnicities	.715 (.648 to .789)	.713 (.646 to .787)	.786 (.672 to .919)	.784 (.671 to .917)
Non-smoker	Reference category			1
Ex-smoker	2.02 (1.82 to 2.24)	2.02 (1.82 to 2.25)	2.23 (2.03 to 2.44)	2.23 (2.04 to 2.44)
Light smoker (1-9 cigarettes/day)	6.59 (6.11 to 7.11)	6.6 (6.12 to 7.12)	5.89 (5.5 to 6.31)	5.9 (5.51 to 6.32)
Moderate smoker (10-19 cigarettes/day)	5.55 (4.94 to 6.23)	5.56 (4.95 to 6.24)	6.28 (5.66 to 6.95)	6.29 (5.67 to 6.96)
Heavy smoker (≥20 cigarettes/day)	9.25 (8.35 to 10.2)	9.27 (8.37 to 10.3)	9.9 (8.88 to 11)	9.93 (8.9 to 11.1)
Family history of lung cancer	1.44 (1.3 to 1.59)	1.44 (1.3 to 1.59)	1.21 (1.09 to 1.35)	1.22 (1.09 to 1.35)
COPD	2.38 (2.3 to 2.45)	2.4 (2.33 to 2.48)	2.42 (2.34 to 2.51)	2.46 (2.37 to 2.54)
Asthma	.939 (.906 to .973)	.943 (.91 to .977)	1.12 (1.08 to 1.16)	1.13 (1.09 to 1.17)
Asbestos	1.33 (1.2 to 1.48)	1.34 (1.21 to 1.48)	NS	NS
Pneumonia	1.21 (1.15 to 1.28)	N/A	1.26 (1.18 to 1.34)	N/A
Venous thromboembolism	1.10 (1.03 to 1.18)	N/A	1.16 (1.09 to 1.24)	N/A
Prior oral cancer	2.55 (2.18 to 2.98)	2.55 (2.18 to 2.99)	2.30 (1.76 to 3.01)	2.31 (1.77 to 3.02)

Prior blood cancer	1.68 (1.52 to 1.86)	1.69 (1.53 to 1.88)	1.90 (1.68 to 2.14)	1.91 (1.7 to 2.16)
Prior renal cancer	1.36 (1.24 to 1.49)	1.36 (1.24 to 1.49)	1.59 (1.36 to 1.86)	1.6 (1.37 to 1.87)
Prior colorectal cancer	1.44 (1.31 to 1.58)	1.44 (1.31 to 1.58)	NS	NS
Prior gastric-oesophageal cancer	1.27 (1.01 to 1.61)	1.28 (1.01 to 1.61)	NS	NS
Prior breast cancer	N/A	N/A	1.56 (1.48 to 1.65)	1.57 (1.49 to 1.65)
Prior cervical cancer	N/A	N/A	1.55 (1.34 to 1.79)	1.55 (1.34 to 1.8)
Prior ovarian cancer	N/A	N/A	1.27 (1.03 to 1.58)	1.28 (1.03 to 1.58)
Prior uterine cancer	N/A	N/A	1.30 (1.08 to 1.55)	1.30 (1.08 to 1.56)
<hr/>				
Non-drinker	Reference category			
Trivial (<1 unit/day)	.941 (.912 to .97)	.94 (.912 to .97)	NS	NS
Light (1-2 unit/day)	.942 (.91 to .976)	.942 (.909 to .976)	NS	NS
Moderate (3-6 unit/day)	.999 (.968 to 1.03)	.998 (.968 to 1.03)	NS	NS
Heavy (7-9 unit/day)	1.13 (1.05 to 1.22)	1.13 (1.05 to 1.22)	NS	NS
Very Heavy (>9 unit/day)	1.11 (1 to 1.24)	1.12 (1 to 1.24)	NS	NS

Notes:

† QCancer2 (2022) means the updated QCancer2 (10-year risk) lung model in this study, original (2015) means the original QCancer (10-year risk) model published in 2015¹⁵, where pneumonia and venous thromboembolism were not in the original model (N/A);

‡ The hazard ratios (HRs) in the above table are adjusted for the fractional polynomial terms for age, BMI, Townsend score, and the interaction between age and smoking status.

N/A means not applicable. NS means non-significant.

Table 4 – Discrimination statistics of the original and updated QCancer2 (10-year risk) lung models in patients aged 25-84 years by sex

Patients aged 25-84 years	Harrell's C	D statistic	R_D^2
QCancer [†] (2015) – Women	0.895 (0.892 - 0.898)	2.79 (2.75 - 2.83)	0.650 (0.644 - 0.656)
QCancer (2015) – Men	0.902 (0.900 - 0.905)	2.77 (2.73 - 2.80)	0.647 (0.641 - 0.652)
QCancer (2022) – Women	0.897 (0.893 - 0.900)	2.81 (2.77 - 2.85)	0.654 (0.648 - 0.660)
QCancer (2022) – Men	0.904 (0.901 - 0.906)	2.79 (2.76 - 2.83)	0.650 (0.645 - 0.656)

Notes: † QCancer (2022) means the updated QCancer2 (10-year risk) lung model in this study,

QCancer (2015) means the original QCancer2 (10-year risk) lung model published in 2015¹⁵, where pneumonia and venous thromboembolism were not in the model;

Table 5 – Discrimination statistics of models for lung cancer screening in three predictive horizons in patients aged 40-84 years (patient subgroup 1)

Patients aged 40-84 years	Harrell's C		D statistic		R_D^2	
	Women	Men	Women	Men	Women	Men
Predictive horizon: 5 year						
QCancer (2022)	0.844 (0.838 - 0.849)	0.852 (0.848 - 0.857)	2.243 (2.195 - 2.291)	2.263 (2.221 - 2.305)	0.546 (0.535 - 0.556)	0.550 (0.541 - 0.559)
LLP _{v2}	0.647 (0.640 - 0.654)	0.654 (0.648 - 0.661)	1.933 (1.885 - 1.981)	1.914 (1.872 - 1.955)	0.471 (0.459 - 0.484)	0.466 (0.456 - 0.477)
LLP _{v3}	0.824 (0.818 - 0.830)	0.826 (0.821 - 0.830)	1.992 (1.944 - 2.040)	1.985 (1.943 - 2.027)	0.486 (0.474 - 0.499)	0.485 (0.474 - 0.495)
LCRAT	0.595 (0.588 - 0.601)	0.604 (0.598 - 0.610)	1.966 (1.918 - 2.014)	1.977 (1.935 - 2.019)	0.480 (0.468 - 0.492)	0.483 (0.472 - 0.493)
Predictive horizon: 6 year						
QCancer (2022)	0.843 (0.837 - 0.848)	0.852 (0.848 - 0.856)	2.241 (2.196 - 2.286)	2.269 (2.230 - 2.309)	0.545 (0.535 - 0.555)	0.551 (0.543 - 0.560)
PLCO _{M2012}	0.560 (0.555 - 0.565)	0.570 (0.565 - 0.575)	1.456 (1.413 - 1.499)	1.362 (1.324 - 1.400)	0.336 (0.323 - 0.349)	0.307 (0.295 - 0.319)
PLCO _{M2014}	0.728 (0.721 - 0.735)	0.741 (0.735 - 0.747)	1.426 (1.381 - 1.470)	1.504 (1.465 - 1.543)	0.327 (0.313 - 0.340)	0.351 (0.339 - 0.363)
Pittsburgh	0.661 (0.654 - 0.668)	0.672 (0.666 - 0.678)	1.954 (1.907 - 2.002)	1.833 (1.705 - 1.960)	0.477 (0.465 - 0.489)	0.445 (0.411 - 0.479)
Predictive horizon: 10 year						
QCancer (2022)	0.842 (0.837 - 0.846)	0.849 (0.846 - 0.853)	2.257 (2.218 - 2.296)	2.256 (2.222 - 2.289)	0.549 (0.540 - 0.557)	0.548 (0.541 - 0.556)
Bach	0.691 (0.685 - 0.697)	0.696 (0.691 - 0.701)	1.751 (1.713 - 1.788)	1.655 (1.622 - 1.688)	0.422 (0.412 - 0.433)	0.395 (0.386 - 0.405)

Table 6 – Discrimination statistics of models for lung cancer screening in three predictive horizons with the TLHC criteria:

Ever-smoker patients aged 55-74 years (patient subgroup 2)

Patients aged 55-74 years	Harrell's C		D statistic		R_D^2	
	Women	Men	Women	Men	Women	Men
Predictive horizon: 5 year						
QCancer (2022)	0.727 (0.715 - 0.739)	0.735 (0.726 - 0.745)	1.925 (1.862 - 1.989)	1.709 (1.655 - 1.762)	0.469 (0.453 - 0.486)	0.411 (0.396 - 0.426)
LLP _{v2}	0.647 (0.635 - 0.659)	0.655 (0.645 - 0.665)	1.560 (1.498 - 1.622)	1.285 (1.232 - 1.338)	0.367 (0.349 - 0.386)	0.283 (0.266 - 0.299)
LLP _{v3}	0.660 (0.648 - 0.672)	0.662 (0.652 - 0.672)	1.634 (1.572 - 1.697)	1.337 (1.284 - 1.390)	0.389 (0.371 - 0.407)	0.299 (0.282 - 0.316)
LCRAT	0.642 (0.629 - 0.655)	0.657 (0.646 - 0.667)	1.573 (1.509 - 1.636)	1.329 (1.275 - 1.383)	0.371 (0.352 - 0.390)	0.297 (0.280 - 0.313)
Predictive horizon: 6 year						
QCancer (2022)	0.726 (0.715 - 0.737)	0.735 (0.726 - 0.743)	1.910 (1.851 - 1.968)	1.717 (1.668 - 1.767)	0.465 (0.450 - 0.481)	0.413 (0.399 - 0.427)
PLCO _{M2012}	0.531 (0.517 - 0.544)	0.545 (0.534 - 0.557)	1.281 (1.226 - 1.335)	0.984 (0.936 - 1.032)	0.281 (0.264 - 0.299)	0.188 (0.173 - 0.203)
PLCO _{M2014}	0.526 (0.513 - 0.540)	0.540 (0.529 - 0.551)	0.734 (0.676 - 0.792)	0.652 (0.602 - 0.701)	0.114 (0.098 - 0.130)	0.092 (0.079 - 0.105)
Pittsburgh	0.643 (0.631 - 0.654)	0.657 (0.648 - 0.666)	1.577 (1.518 - 1.636)	1.318 (1.231 - 1.406)	0.373 (0.355 - 0.390)	0.293 (0.266 - 0.321)
Predictive horizon: 10 year						
QCancer (2022)	0.724 (0.715 - 0.733)	0.731 (0.723 - 0.738)	1.896 (1.847 - 1.945)	1.717 (1.675 - 1.759)	0.462 (0.449 - 0.475)	0.413 (0.401 - 0.425)
Bach	0.575 (0.566 - 0.585)	0.586 (0.577 - 0.595)	1.345 (1.298 - 1.392)	1.112 (1.071 - 1.153)	0.302 (0.287 - 0.316)	0.228 (0.215 - 0.241)

Figures

Figure 1 – Calibration plots for the Qcancer2 (10-year risk lung model) in the three predictive horizons by sex













Figure 2 – Calibration plots for smokers and non-smokers aged 40-84 years old (patient subgroup 1) in the three predictive horizons and by sex

5-year predictive horizon



6-year predictive horizon



10-year predictive horizon
















Figure 3 – Calibration plots for ever smokers aged 55–74 years (patient subgroup 2, the targeted lung health check criteria) in the three predictive horizons and by sex

5-year predictive horizon



6-year predictive horizon



10-year predictive horizon







Figure 4 – Decision curve analysis for patient subgroup 1 (smokers and non-smokers aged 40-84 years old, including never smokers)




Figure 5 – Decision curve analysis for patient subgroup 2 (ever-smokers aged 55-74 years old, the TLHC criteria)

